-
New therapies with a promise
Providing patients with new cures -
Drug discoveries based on Nucleoside Library Platform
New drugs for anti-cancer, anti-inflammation/fibrosis, and anti-virus
Pipeline
Innovative solutions to novel drug development
Differential modulation of A3AR analogues of agonist and antagonist are currently being evaluated for its pharmacology and safety, which has led initial candidates of preclinical and clinical development in the areas of cancer, ophthalmology and inflammation. 보유중인 신약 후보 물질인 A3AR을 중심으로 항암,항염 등 다양한 적응증에 대한 치료제 개발을 위하여 비임상 및 임상 시험을 진행하고 있습니다.
Management & R&D
Lak Shin Jeong, Ph.D
정낙신 대표이사
서울대 약학대학 약학과 교수
Sang Kook Lee, Ph.D 이상국 서울대 약학대학 제약학과 교수
Wan Seok Jeong CEO, MBA 정완석 대표이사
